Navigation Links
High-Performing Healthcare Organizations Have Seven Qualities in Common
Date:3/25/2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)...IANAPOLIS A study published in the May/June issue ...trial providing a scientifically valid look at wha... programs that serve low-income individuals. The s...leaders struggling to meet the needs of individual...ome disease management efforts, even among relativ...
(Date:5/12/2008)...oject proceeds despite non-compliance with Califor... Act (CEQA)., LOS ANGELES, May 12 /PRNewswire-USN...PHCMC) today went ahead with the planned expansion... Court Judge Thomas I. McKnew,Jr. has upheld char...awed.,The groundbreaking ceremony held today appea...
(Date:5/12/2008)...T. DAVID,S, Bermuda and COPENHAGEN, Denmark, May 1...O Pharma announced today,that the United States Fo...New Drug Application (NDA) for Taclonex Scalp(R) (...e 0.064%) Topical Suspension. LEO Pharma submitted...2007. Taclonex Scalp(R) is,a topical suspension co...
(Date:5/12/2008)...HOENIX, May 12 /PRNewswire-FirstCall/ -- NutraCea ...ilized rice bran (SRB), nutrient research and,tech...first quarter ended,March 31, 2008. Consolidated n...t quarter of 2008, compared to consolidated net re...07. The $3.1 million increase was,primarily due to...
Breaking Medicine News(10 mins):Health News:Chronic disease management: Does it improve health and save money? 2Health News:Providence Holy Cross Medical Center Ignores Community, Environmental Concerns With Planned Expansion of Mission Hills Facility 2Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 2Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 3Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 4Health News:NutraCea Announces First Quarter 2008 Financial Results 2Health News:NutraCea Announces First Quarter 2008 Financial Results 3Health News:NutraCea Announces First Quarter 2008 Financial Results 4Health News:NutraCea Announces First Quarter 2008 Financial Results 5Health News:NutraCea Announces First Quarter 2008 Financial Results 6
..., a new type of antidepressant, called venlafaxine... social anxiety disorder (SAD) people experience f...talking with other people which can make both work...those with SAD suffer other mental health problems...
...ved that, people suffering from heat diseases are ...ffective exercise, but for a few it might prove to...s may wonder if it is still safe to enjoy a game o...ave now addressed this question. They followed 15 ...
...rs, that three years on, a group of kidney cancer ...thanks to a new procedure. Researchers at the Univ...on for kidney cancer, called interventional-MRI re...ic resonance imaging to guide a surgical probe whi...
...igh levels of the amino acid homocysteine may incr...sease, researchers report. It is still too soon to... reduce the risk of Alzheimer's// and other types ...h investigating. Prior research has shown that ele...
Other Medicine News:Health News:High Levels of Protein Linked to Brain Shrinkage 2
(Date:5/12/2008)...,Intercell,) to acquire Iomai Corporation (,Iomai,...or USD 6.60 per share of Iomai,s common stock re...f approximately USD 189 million (EUR 122 million...or-stock exchange for approximately 41 percent of...shareholders for,approximately 1.7 million Interce...
(Date:5/12/2008)...12 /PRNewswire-USNewswire/ -- The Alliance for Lup...ge of a resolution,supporting the goals and ideals...lly on Mother,s Day. The resolution, introduced by...R-ME) calls on all Americans to take the,week of M...emselves on,women,s health issues, and recognizes ...
(Date:5/12/2008)...djust their function like a radio dial, not an on/...toimmune disease may develop,late in life, MEMP.... Jude Children,s,Research Hospital study shows th...o not use simple on/off switches to govern the cel...nd function. Rather, they,possess sophisticated mo...
(Date:5/12/2008)...mising neurological recovery in severely-injured, ...reated with Cethrin, HOPKINTON, Mass., May 12 /PR...c. (Nasdaq: ALSE ) today announced 12-month inter...hrin, a proprietary recombinant,protein that is be...r and,sensory function after spinal cord injury, o...
Breaking Medicine Technology:Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 2Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 3Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 4Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 5Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 6Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 7Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 8Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 9Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 10Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 11Lupus Under the Spotlight: U.S. Congress Shows Support for Women's Health Issues 2St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity 2St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity 3St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity 4Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 2Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 3Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 4Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury 5Thermo Fisher Scientific to Present at Upcoming Investor Conferences 535 1Thermo Fisher Scientific to Present at Upcoming Investor Conferences 535 2Hypertension 3A Journal of the American Heart Association Rapid Access Reports 3A Hispanics Hypertension Better Controlled With Equal Access to Care 256 1Hypertension 3A Journal of the American Heart Association Rapid Access Reports 3A Hispanics Hypertension Better Controlled With Equal Access to Care 256 2Hypertension 3A Journal of the American Heart Association Rapid Access Reports 3A Hispanics Hypertension Better Controlled With Equal Access to Care 256 3Hypertension 3A Journal of the American Heart Association Rapid Access Reports 3A Hispanics Hypertension Better Controlled With Equal Access to Care 256 4New Drug No Substitute for Standard Blood Clot Therapy 1129 1New Drug No Substitute for Standard Blood Clot Therapy 1129 2New Drug No Substitute for Standard Blood Clot Therapy 1129 3Congress Poised to Add Millions of Uninsured Children to Successful Bipartisan Health Plan 1125 1Congress Poised to Add Millions of Uninsured Children to Successful Bipartisan Health Plan 1125 2Congress Poised to Add Millions of Uninsured Children to Successful Bipartisan Health Plan 1125 3
...ll/ -- Forest,Laboratories, Inc. and Cypress Biosc...ine results from a 1,196 patient randomized,three...hase III,study demonstrate statistically significa...nt of fibromyalgia syndrome. At this time,the comp...ne,results and further analyses will be completed ...
...enous Stent, BARCELONA, Spain, May 23, 2007 /PRNew...Bio-engineered R stent compares favorably,to that ...ombosis,is minimized with the Genous stent, accord...presented today by Robbert de,Winter, M.D., Ph.D.,...from more than 120 sites in 29 countries, follow-u...
Other Medicine Technology:Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 2Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 3Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 4Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 5Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 6Efficacy of OrbusNeich's Genous Bio-Engineered R Stent Compares,Favorably to Drug-Eluting Stents 2Efficacy of OrbusNeich's Genous Bio-Engineered R Stent Compares,Favorably to Drug-Eluting Stents 3
...ndard/Conventional. Stainless steel. Lamp supplied...high quality standard incandescent laryngoscope bl...ually refined through many years of use the world ...e manufactured to exacting specifications from the...
...ndard/Conventional. Stainless steel. Lamp supplied...high quality standard incandescent laryngoscope bl...ually refined through many years of use the world ...e manufactured to exacting specifications from the...
...ndard/Conventional Blade. Stainless steel. Lamp su...on of high quality standard incandescent laryngosc...continually refined through many years of use the ...hey are manufactured to exacting specifications fr...
...ch Snap-Light™ laryngoscope blades are desig... fiber optic bundle can be removed to simplify cle...ique snap-on mechanism eliminates screws that can ...hangeable with other green coded fiber optic syste...
Medicine Products: